Nucala (mepolizumab) Prior Authorization Protocol
|
|
- Katrina Chambers
- 5 years ago
- Views:
Transcription
1 Nucala (mepolizumab) Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutic Subcommittee. Drug Requiring Prior Authorization Review: Nucala (mepolizumab) Formulary Alternative: None Criteria: A. Drug: Nucala 1. Diagnosis: Severe asthma with eosinophilic phenotype Criteria: Must meet all of the following requirements: a. Age 12 or older b. Diagnosis of severe eosinophilic asthma confirmed by 1 of the following laboratory results: i. Blood eosinophil counts greater than or equal to 150 cells/microliter at initiation of therapy. ii. Blood eosinophil counts greater than or equal to 300 cells/microliter in the prior year (365 days). b. Asthma is inadequately controlled by the following combination therapy: i. High-dose inhaled corticosteroids (ICS) given in combination with a long-acting beta2-agonist (LABA). c. Member has been compliant to the controller therapy for the past 6 months (180 days) according to refills record, and will continue the controller therapy. d. Documentation of symptomatic asthma despite regular use of therapies, as demonstrated by 1 of the following: i. Two or more asthma exacerbations in the previous year (365 days).
2 ii. Hospitalization due to asthma exacerbation. e. Pretreatment forced expiratory volume in 1 second (FEV1) less than 80% predicted. Specialist: Allergist or Pulmonologist Quantity Limit: N/A Duration of Therapy: 6 months (180 days) Reauthorization Criteria: Must meet all of the following requirements: a. Recent pharmacy claim within 6 months (180 days) of request. b. Confirmed stability or no disease progression. Duration of Reauthorization: 6 months (180 days) 2. Diagnosis: Eosinophilic granulomatosis with polyangiitis Criteria: Must meet all of the following requirements: a. Age 18 or older b. Confirmed diagnosis by the all of the following: i. History or presence of asthma ii. Blood eosinophil level of 10% or an absolute eosinophil count of more than 1000 cells per cubic millimeter; OR iii. the presence of two or more criteria that are typical of eosinophilic granulomatosis with polyangiitis (i.e. histopathological evidence of eosinophilic vasculitis, perivascular eosinophilic infiltration, or eosinophil-rich granulomatous inflammation; neuropathy; pulmonary infiltrates; sinonasal abnormality; cardiomyopathy; glomerulonephritis; alveolar hemorrhage; palpable purpura; or antineutrophil cytoplasmic antibody [ANCA] positivity). c. Concurrently on a stable dose of oral corticosteroids (i.e. prednisone or prednisolone). Specialist: Allergist or Pulmonologist Quantity Limit: N/A Duration of Therapy: 6 months (180 days) Reauthorization Criteria: Must meet all of the following requirements: a. Recent pharmacy claim within 6 months (180 days) of request.
3 b. Confirmed stability or no disease progression. Duration of Reauthorization: 6 months (180 days) Clinical Justification: FDA-Approved Indications Add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype. Eosinophilic granulomatosis with polyangiitis. Limitation of use Not indicated for treatment of other eosinophilic conditions. Not indicated for the relief of acute bronchospasm of status asthmaticus. Clinical Study: MENSA In a randomized, double-blind placebo study, 576 patients were evaluated with recurrent asthma exacerbations (history of 2 or more exacerbations in the previous year), despite high-dose regular use of inhaled (with or without systemic) glucocorticoids plus an additional controller in the previous year. Presence of eosinophilic inflammation is required, defined as blood eosinophil count 150/mcL at screening or 300/mcL at some point in the previous year. Patients were randomized to receive mepolizumab 75mg intravenously, mepolizumab 100mg subcutaneously or placebo every 4 weeks for 32 weeks. As a result, the rate of exacerbations was reduced by 47% in the intravenous mepolizumab group, 53% in the subcutaneous mepolizumab group, as compared with those receiving placebo (p <0.001 for both comparisons). Furthermore, exacerbations necessitating an emergency department visit or hospitalization were reduced by 32% in the intravenous mepolizumab group by 61% in the subcutaneous mepolizumab group. Significant improvement from baseline FEV 1 was noted, 100 ml greater in the intravenous mepolizumab group (p= 0.02), and 98mL improvement in the subcutaneous mepolizumab group (p= 0.03) in comparison to placebo, respectively. The improvement from baseline St. George s Respiratory Questionnaire (SGRQ) was 6.4 points and 7.0 points greater in the intravenous and subcutaneous mepolizumab groups, respectively, than in the placebo group (p< 0.001), and the improvement in the Asthma Control Questionnaire (ACQ-5) score was 0.42 points and 0.44 points greater in the two study group than placebo (p< 0.001), respectively. The safety profile was comparable to that of placebo.
4 Clinical Study: SIRIUS In a randomized, double-blind study, 135 patients were enrolled with severe eosinophilic asthma (300 blood eosinophils/mcl during the 12 months prior to the study entry or 150 eosinophils/mcl during the optimization phase), despite daily oral glucocorticoid treatment in addition to regular use of high-dose inhaled corticosteroids plus an additional controller(s). Patients were randomized to receive mepolizumab 100mg or placebo subcutaneously every 4 weeks for 20 weeks. As a result, the likelihood of a reduction in the glucocorticoid-dose was 2.39 times greater in the mepolizumab group than in the placebo group (p= 0.008), and the mean reduction from baseline was 50%, as compared with no reduction in the placebo group (p= 0.007). In addition, patients in the mepolizumab group despite receiving a lower glucocorticoid dose, resulted in a 32% relative reduction in the annualized rate of exacerbation (p= 0.04) and a reduction of 0.52 points with respect to asthma symptoms (p= 0.004). The safety profile of mepolizumab was similar to that of placebo. Clinical Study: EGPA In a randomized, placebo-controlled multicenter, 52 week trial, a total of 136 patients with eosinophilic granulomatosis with polyangiitis (EGPA or Churg-Strauss syndrome) were enrolled. Patients receiving 300mg of mepolizumab achieved a significantly greater accrued time in remission compared to placebo. Significantly higher proportion of subjects receiving 300mg of mepolizumab achieved remission at week 36 and week 48 compared to placebo, significantly more subjects receiving mepolizumab achieved remission within the first 24 weeks and remained in remission for the remainder of the 52 week study period compared to placebo (19% vs 1%). Cochrane Database Systematic Review 2015 Eight randomized controlled placebo studies of mepolizumab in adults and children with asthma were included in the systematic review that evaluated efficacy of mepolizumab in reducing exacerbations and improving health-related quality of life (HRQoL). The systematic review concludes that mepolizumab can lead to an improvement in health-related quality of life scores and reduce asthma exacerbation in people with severe eosinophilic asthma. Furthermore, the data review was limited by the fact that the intravenous route is not currently licensed for mepolizumab, and the evidence for the currently licensed subcutaneous route is limited to a single study in patients with severe eosinophilic asthma.
5 Guidelines from the National Asthma Education and Prevention Program: Expert Panel Report
6 References: 1. Nucala [package insert]. GlaxoSmithKline LLC, Philadelphia, PA. 12/ Bel EH, Wenzel SE, Thompson PJ, et al. N Engl J Med Sep; 371(13): Epub 2014 Sep Powell C, Milan SJ, Dwan K, et al. Cochrane Database Syst Rev. 2015; 7:CD Ortega HG, Liu MC, Pavord ID, et al. N Engl J Med Sep;371(13): National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. NIH Publication Number October Available at: Accessed on June 4, National Heart, Lung, and Blood Institute. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma (EPR-3). September Available at: Accessed on December 21, 2015.
7 Change Control Date Change 02/21/2018 Updated indications to include Eosinophilic granulomatosis with polyangiitis and added criteria Added clinical study for new indication: EGPA Duration changed from 12 months to 6 months
Pharmacy Management Drug Policy
SUBJECT: : Nucala (mepolizumab), Cinqair (reslizumab), & Fasenra (benralizumab) POLICY NUMBER: Pharmacy-62 EFFECTIVE DATE: 12/15 LAST REVIEW DATE: 3/5/2018 If the member s subscriber contract excludes
More informationRESPIRATORY INTERLEUKINS (CINQAIR, FASENRA, AND NUCALA )
UnitedHealthcare Community Plan Medical Benefit Drug Policy RESPIRATORY INTERLEUKINS (CINQAIR, FASENRA, AND NUCALA ) Policy Number: CS2018D0055D Effective Date: May 1, 2018 Table of Contents Page INSTRUCTIONS
More informationIL-5 Antagonists (IgG1 kappa) Fasenra (benralizumab) Nucala (mepolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.07 Subject: IL-5 Antagonists (IgG1 kappa) Page: 1 of 6 Last Review Date: June 22, 2018 IL-5 Antagonists
More informationand one and and not any and and and
RESPIRATORY INTERLEUKINS (CINQAIR, FASENRA, AND NUCALA ) UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2019D0055G Effective Date: March 1, 2019 Instructions for Use Table of Contents
More informationRESPIRATORY INTERLEUKINS (CINQAIR, FASENRA, AND NUCALA )
RESPIRATORY INTERLEUKINS (CINQAIR, FASENRA, AND NUCALA ) UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2018D0055D Effective Date: March 1, 2018 Table of Contents Page INSTRUCTIONS
More informationNucala. Nucala (mepolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.07 Subject: Nucala Page: 1 of 5 Last Review Date: December 2, 2016 Nucala Description Nucala (mepolizumab)
More informationRESPIRATORY INTERLEUKINS (CINQAIR, FASENRA, AND NUCALA )
RESPIRATORY INTERLEUKINS (CINQAIR, FASENRA, AND NUCALA ) UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: PHA037 Effective Date: September 1, 2018 Table of Contents Page INSTRUCTIONS
More informationClinical Policy: Mepolizumab (Nucala) Reference Number: ERX.SPA.214 Effective Date:
Clinical Policy: (Nucala) Reference Number: ERX.SPA.214 Effective Date: 07.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Interleukin (IL)-5 Antagonists: Mepolizumab and Reslizumab Table of Contents Coverage Policy... 1 General Background... 3 Coding/Billing Information... 5
More informationPolicy Effective 4/1/2018
Corporate Medical Policy Interleukin-5 Antagonists Notification File Name: Origination: Last CAP Review: Next CAP Review: Last Review: interleukin_5_antagonists 2/2016 11/2017 11/2018 2/2018 Policy Effective
More informationClinical Policy: Mepolizumab (Nucala) Reference Number: ERX.SPA.214 Effective Date:
Clinical Policy: (Nucala) Reference Number: ERX.SPA.214 Effective Date: 07.01.16 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Nucala) Reference Number: CP.PHAR.200 Effective Date: 04.01.16 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder at
More informationNon-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.
NUCALA (mepolizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Nucala) Reference Number: CP.PHAR.200 Effective Date: 04.01.16 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder at
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Injectable Asthma Agents Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Injectable Asthma Agents Xolair (omalizumab) Prime Therapeutics will
More informationXolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit)
Line of Business: All Lines of Business Effective Date: August 16, 2017 Xolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit) This policy has been developed through review
More informationERS Investor & Analyst Event. Munich Tuesday 9 th September 2014
ERS Investor & Analyst Event Munich Tuesday 9 th September 2014 Darrell Baker SVP, Global Head of Respiratory Agenda GSK s Respiratory Portfolio Eosinophils Research in COPD Eosinophils Clinical Experience
More informationTargeting Interleukin-5 in Patients With Severe Eosinophilic Asthma: A Clinical Review
Targeting Interleukin-5 in Patients With Severe Eosinophilic Asthma: A Clinical Review Christine Lam, PharmD, BCPS; Kunal J. Shah, PharmD; and Rupal Mansukhani, PharmD INTRODUCTION Asthma is a chronic
More informationOmalizumab (Xolair) NHLBI normal ranges by age for FEV 1/FVC 8-19 years of age 85%; years of age 80%;
DRAFT Medical Coverage Policy Injectable Agents for Asthma and Chronic Idiopathic Urticaria Fasenra, Nucala, Xolair, Cinqair EFFECTIVE DATE: 03 01 2018 POLICY LAST UPDATED: 03 20 2018 OVERVIEW This policy
More informationBrooke L. Gildon, Pharm.D., BCPS, BCPPS, AE C
Brooke L. Gildon, Pharm.D., BCPS, BCPPS, AE C Associate Professor of Pharmacy Practice Southwestern Oklahoma State University College of Pharmacy Oklahoma Society of Health System Pharmacists Annual Meeting
More informationNucala (mepolizumab injection for subcutaneous use)
Nucala (mepolizumab injection for subcutaneous use) Policy Number: 5.01.612 Last Review: 01/2018 Origination: 02/2016 Next Review: 02/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationDo We Need Biologics in Pediatric Asthma Management?
Do We Need Biologics in Pediatric Asthma Management? Ting Fan LEUNG, MBChB, MD, FRCPCH, FAAAAI Professor and Chairman Department of Paediatrics The Chinese University of Hong Kong Asthma and Allergy by
More informationStudy Investigators/Centers: GSK sponsored studies MEA112997, MEA115588, and MEA and a proof of concept investigator sponsored study CRT110184
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationBiologic Therapy in the Management of Asthma. Nabeel Farooqui, MD
Biologic Therapy in the Management of Asthma Nabeel Farooqui, MD None Disclosures Objectives Define severe asthma phenotypes and endotypes Describe the role of biologics in asthma management Review pivotal
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Fasenra) Reference Number: CP.PHAR.## Effective Date: 01.16.18 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationDrug Class Monograph
Drug Class Monograph Class: Inhaled Corticosteroids Drugs: Aerospan (flunisolide), Advair Diskus, Advair HFA (fluticasone/salmeterol), Alvesco (ciclesonide), Arnuity Ellipta (fluticasone furoate), Asmanex
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Xolair (omalizumab) Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xolair (omalizumab) Prime Therapeutics will review Prior Authorization requests.
More information2017 Blue Cross and Blue Shield of Louisiana
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationHCT Medical Policy. Bronchial Thermoplasty. Policy # HCT113 Current Effective Date: 05/24/2016. Policy Statement. Overview
HCT Medical Policy Bronchial Thermoplasty Policy # HCT113 Current Effective Date: 05/24/2016 Medical Policies are developed by HealthyCT to assist in administering plan benefits and constitute neither
More informationCTAF Overview. Agenda. Evidence Review. Mepolizumab (Nucala, GlaxoSmithKline plc.) for the Treatment of Severe Asthma with Eosinophilia
CTAF Overview Mepolizumab (Nucala, GlaxoSmithKline plc.) for the Treatment of Severe Asthma with Eosinophilia February 12, 2016 Core program of the Institute for Clinical and Economic Review (ICER) Goal:
More informationSEVERE ASTHMA NUCALA 100MG SUBCUTANEOUS INJECTION THE FIRST TARGETED ANTI IL-5 ADD-ON TREATMENT FOR ADULTS WITH SEVERE REFRACTORY EOSINOPHILIC ASTHMA
SEVERE ASTHMA NUCALA 100MG SUBCUTANEOUS INJECTION THE FIRST TARGETED ANTI ADD-ON TREATMENT FOR ADULTS WITH SEVERE REFRACTORY EOSINOPHILIC ASTHMA FIND OUT MORE VISIT - WWW.NUCALA.CO.UK Vial not actual size
More informationBiologics in asthma Are we turning the corner? Roland Buhl Pulmonary Department Mainz University Hospital
Biologics in asthma Are we turning the corner? Roland Buhl Pulmonary Department Mainz University Hospital Biologics in asthma - are we turning the corner? Allergic asthma anti - IgE Allergic airway inflammation
More informationSubject: Fasenra (benralizumab) Original Effective Date: 7/10/2018. Policy Number: MCP-319. Revision Date(s):
Subject: Fasenra (benralizumab) Original Effective Date: 7/10/2018 Policy Number: MCP-319 Revision Date(s): Review Date(s): MCPC Approval Date: 7/10/2018 DISCLAIMER This Molina Clinical Policy (MCP) is
More informationMepolizumab (asthma)
IQWiG Reports Commission No. A16-33 Mepolizumab (asthma) Addendum to Commission A16-03 1 Addendum Commission:A16-33 Version: 1.0 Status: 29 June 2016 1 Translation of addendum A16-33 Mepolizumab (Asthma)
More informationXOLAIR (omalizumab) Prior Authorization
MP9309 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes as shown below May only be prescribed by Allergy, Pulmonary, Immunology or Dermatology specialists
More informationBUDESONIDE AND FORMOTEROL (SYMBICORT ): Α A REVIEW
Volume 23, Issue 3 December 2007 BUDESONIDE AND FORMOTEROL (SYMBICORT ): A REVIEW Donna L. Smith, Pharm. D. Candidate More than 22 million people in the United States have asthma according to the Centers
More informationDrug Prior Authorization Guideline NUCALA (mepolizumab)
Drug Prior Authorization Guideline MB9914 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes as shown below Restricted to Pulmonology, Allergy, and
More informationCinqair (reslizumab injection for intravenous use)
Cinqair (reslizumab injection for intravenous use) Policy Number: 5.02.522 Last Review: 04/2018 Origination: 04/2016 Next Review: 04/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationBiologics in Asthma: Present and Future
Biologics in Asthma: Present and Future Flavia Hoyte, MD Associate Professor of Medicine Fellowship Training Program Director Division of Allergy and Immunology National Jewish Health and University of
More informationMEDICAL ASSISTANCE BULLETIN
ISSUE DATE January 6, 2016 SUBJECT EFFECTIVE DATE January 20, 2016 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of COPD Agents Pharmacy Service Leesa M. Allen, Deputy Secretary
More informationand will be denied as not medically necessary** if not met. This criterion only applies to the initial
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Xolair (omalizumab) Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xolair (omalizumab) Prime Therapeutics will review Prior Authorization requests.
More informationreslizumab (Cinqair )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationbenralizumab (Fasenra )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More information#1 cause of school absenteeism in children 13 million missed days annually
Asthma Update 2013 Jennifer W. McCallister, MD, FACP, FCCP Associate Professor Pulmonary & Critical Care Medicine The Ohio State University Wexner Medical Center Disclosures None 2 Objectives Review burden
More informationClinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46. Line of Business: Medicaid
Clinical Policy: (Daliresp) Reference Number: CP.PMN.46 Effective Date: 11/11 Last Review Date: 08/17 Line of Business: Medicaid See Important Reminder at the end of this policy for important regulatory
More informationCost-effectiveness of mepolizumab (Nucala ) as an add-on treatment for severe refractory eosinophilic asthma in adult patients.
Cost-effectiveness of mepolizumab (Nucala ) as an add-on treatment for severe refractory eosinophilic asthma in adult patients. The NCPE has issued a recommendation regarding the cost-effectiveness of
More informationReview. Key words : asthma, benralizumab, interleukin-5, mepolizumab, reslizumab. Introduction
Showa Univ J Med Sci 30 1, 11 25, March 2018 Review Comparative Efficacy and Safety of Anti-Interleukin-5 Therapies and Placebo in Patients with Uncontrolled Eosinophilic Asthma : A Systematic Review and
More informationClinical Policy: Omalizumab (Xolair) Reference Number: ERX.SPA.141 Effective Date: Last Review Date: 08.17
Clinical Policy: (Xolair) Reference Number: ERX.SPA.141 Effective Date: 03.01.14 Last Review Date: 08.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationDUPIXENT (dupilumab) subcutaneous injection
DUPIXENT (dupilumab) subcutaneous injection Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationDraft Report. December 21, Institute for Clinical and Economic Review
Mepolizumab (Nucala, GlaxoSmithKline plc.) for the Treatment of Severe Asthma with Eosinophilia: Effectiveness, Value, and Value- Based Price Benchmarks Draft Report December 21, 2015 Institute for Clinical
More informationIs reslizumab effective in improving quality of life and asthma control in adolescent and adult patients with poorly controlled eosinophilic asthma?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2018 Is reslizumab effective in improving
More informationClinical Policy: Fluticasone/Salmeterol (Advair Diskus, Advair HFA) Reference Number: CP.PMN.31 Effective Date: 08/16 Last Review Date: 08/17
Clinical Policy: (Advair Diskus, Advair HFA) Reference Number: CP.PMN.31 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this
More informationUsefulness of Bronchial Thermoplasty for Patients with a Deteriorating Lung Function
doi: 10.2169/internalmedicine.8965-17 http://internmed.jp CASE REPORT Usefulness of Bronchial Thermoplasty for Patients with a Deteriorating Lung Function Daisuke Minami, Chihiro Ando, Takamasa Nakasuka,
More informationCase-Compare Impact Report
Case-Compare Impact Report October 8, 20 For CME Activity: Developed through an independent educational grant from Genentech: Moderate to Severe Persistent Asthma: A Case-Based Panel Discussion (March
More informationLearning the Asthma Guidelines by Case Studies
Learning the Asthma Guidelines by Case Studies Timothy Craig, DO Professor of Medicine and Pediatrics Distinguished Educator Penn State University Hershey Medical Center Objectives 1. Learn the Asthma
More informationTo report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at or FDA at FDA-1088 or
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NUCALA safely and effectively. See full prescribing information for NUCALA. NUCALA (mepolizumab)
More informationInhaled Corticosteroids Drug Class Prior Authorization Protocol
Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Fluticasone/Salmeterol (Advair Diskus, Advair HFA) Reference Number: CP.PMN.31 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan See Important Reminder
More informationThe Pharmacist s Role in Managing Severe Asthma. This activity is supported by an educational grant from Genentech. Educational Objectives
The Pharmacist s Role in Managing Severe Asthma Jennifer M. Malinowski, PharmD, RPh Assistant Dean, Academic Affairs Associate Professor, Pharmacy Practice Wilkes University School of Pharmacy Wilkes-Barre,
More informationAsma e BPCO: le strategie terapeutiche
Asma e BPCO: le strategie terapeutiche Dott. Marco Contoli ctm@unife.it Sezione di Medicina Interna e Cardio-Respiratoria Dipartimento di Scienze Mediche Università di Ferrara COPD Definition Chronic Obstructive
More informationLocal Omalizumab Treatment Protocol (For children 6 to <12 years of age)
Local Omalizumab Treatment Protocol (For children 6 to
More informationOriginal. Koichi ANDO 1 2, Akihiko TANAKA 1, Tsukasa OHNISHI 1, Shin INOUE 2 and Hironori SAGARA 1
Showa Univ J Med Sci 30 2, 297 307, June 2018 Original Effectiveness of Therapeutic Monoclonal Antibodies for Asthma Control in Uncontrolled Eosinophilic Asthma A Meta-analysis of Randomized Controlled
More informationInhaled Corticosteroids Drug Class Prior Authorization Protocol
Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationNew Drug Evaluation: mepolizumab for injection
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationThe Acute & Maintenance Treatment of Asthma via Aerosolized Medications
The Acute & Maintenance Treatment of Asthma via Aerosolized Medications Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Associate Professor and Chairman Department of Respiratory Therapy Objectives Define Asthma.
More informationMepolizumab versus placebo for asthma(review)
Cochrane Database of Systematic Reviews Mepolizumab versus placebo for asthma(review) PowellC,MilanSJ,DwanK,BaxL,WaltersN PowellC,MilanSJ,DwanK,BaxL,WaltersN. Mepolizumab versus placebo for asthma. Cochrane
More informationActhar Gel. H. P. Acthar Gel (corticotropin; ACTH) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.10 Subject: Acthar Gel Page: 1 of 5 Last Review Date: December 2, 2016 Acthar Gel Description H. P.
More informationSubject: Bronchial Thermoplasty
Subject: Bronchial Thermoplasty Guidance Number: MCG-171 Revision Date(s): Original Effective Date: 6/12/14 Medical Coverage Guidance Approval Date: 6/12/14 PREFACE This Medical Guidance is intended to
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: bronchial_thermoplasty 10/2010 3/2018 3/2019 3/2018 Description of Procedure or Service Bronchial thermoplasty
More informationBiologic Agents in the treatment of Severe Asthma
Biologic Agents in the treatment of Severe Asthma Daniel L Maxwell, D.O., FACOI, FAASM Clinical Assistant Professor of Medicine Michigan State University College of Osteopathic Medicine College of Human
More informationSevere Asthma & Exacerbations: Dawn of a New Era?
Severe Asthma & Exacerbations: Dawn of a New Era? Christophe von Garnier Department of Pulmonary Medicine Syndromes, Phenotypes & Endotypes Asthma Syndrome Variable symptoms, expiratory airflow limitation,
More informationCinqair. (reslizumab) New Product Slideshow
Cinqair (reslizumab) New Product Slideshow Introduction Brand name: Cinqair Generic name: Reslizumab Pharmacological class: Interleukin-5 antagonist Strength and Formulation: 100mg/10mL; solution for IV
More informationTraiter l asthme sévère par le phénotype. Dr. Alain Michils CUB-Hôpital Erasme
Traiter l asthme sévère par le phénotype Dr. Alain Michils CUB-Hôpital Erasme Darwin 25 mars 2017 Step 5 treatment (GINA 2016) STEP 5 STEP 4 PREFERRED CONTROLLER CHOICE STEP 1 STEP 2 Low dose ICS STEP
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 07/05/18 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:
CINQAIR (reslizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationIndirect Comparison of Dupilumab and Mepolizumab Treatments for Uncontrolled Eosinophilic Asthma Bayesian Analysis of Randomized Controlled Trials
Showa Univ J Med Sci 30 2, 189 196, June 2018 Original Indirect Comparison of Dupilumab and Mepolizumab Treatments for Uncontrolled Eosinophilic Asthma Bayesian Analysis of Randomized Controlled Trials
More informationXolair (omalizumab) Limitation of Use: Xolair is not indicated for treatment of other forms of urticaria.
Xolair (omalizumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 11/18/2003 Current Effective Date: 12/01/2017TBD POLICY A. INDICATIONS The indications below
More informationQUANTITY LIMIT CRITERIA. BROVANA (arformoterol tartrate) SEREVENT DISKUS (salmeterol) STRIVERDI RESPIMAT (olodaterol)
Carelirst. +.V Family of health care plans DRUG CLASS COMBINATIONS QUANTITY LIMIT CRITERIA LONG ACTING BETA2-ADRENERGIC AGONIST, ORAL INHALATION BRAND NAME (generic) LONG-ACTING BETA2-ADRENERGIC AGONISTS:
More informationClinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46 Effective Date: Last Review Date: 08.18
Clinical Policy: (Daliresp) Reference Number: CP.PMN.46 Effective Date: 11.01.11 Last Review Date: 08.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationJamie Lee Memorial Lecture ( ) Targets and Outcomes: Mepolizumab, Benralizumab, Reslizumab
Jamie Lee Memorial Lecture (1958-2017) Targets and Outcomes: Mepolizumab, Benralizumab, Reslizumab Larry Borish, M.D. Professor of Medicine and Microbiology University of Virginia Conflict of Interest
More informationMonoclonal antibody therapy for severe asthma
INFORMATION PAPER FOR PRIMARY HEALTHCARE PROFESSIONALS MONOCLONAL ANTIBODY THERAPY Monoclonal antibody therapy for severe asthma KEY POINTS Benralizumab, mepolizumab and omalizumab are monoclonal antibody
More informationControversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies
Controversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies Stanley J. Szefler, MD Helen Wohlberg and Herman Lambert Chair in Pharmacokinetics, Head, Pediatric
More informationThe methodology behind GINA and EPR-3 medication recommendations: Stepwise treatment in asthma
The methodology behind GINA and EPR-3 medication recommendations: Stepwise treatment in asthma Maureen George PhD RN AE-C FAAN Columbia University mg3656@cumc.columbia.edu Faculty Disclosures Maureen George
More information2. Does the patient have chronic urticaria? Y N
Pharmacy Prior Authorization AETA BETTER HEALTH PESLVAIA & AETA BETTER HEALTH KIDS Xolair (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationMepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
The new england journal of medicine Original Article Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis M.E. Wechsler, P. Akuthota, D. Jayne, P. Khoury, A. Klion, C.A. Langford, P.A.
More informationjournal of medicine The new england Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma Abstract
The new england journal of medicine established in 1812 september 25, 2014 vol. 371 no. 13 Oral Glucocorticoid-Sparing Effect of in Eosinophilic Asthma Elisabeth H. Bel, M.D., Ph.D., Sally E. Wenzel, M.D.,
More informationAsthma Upate 2018: What s New Since the 2007 Asthma Guidelines of NAEPP?
10:50-11:50am Asthma Update 2018: What s New Since the 2007 National Asthma Guidelines? SPEAKER Christopher H. Fanta, MD Disclosures The following relationships exist related to this presentation: Christopher
More informationAerospan (flunisolide)
STRENGTH DOSAGE FORM ROUTE GPID 80mcg/actuation HFA aerosol inhaler w/ Inhaled 35718 8.9 g/canister adapter MANUFACTURER Meda Pharmaceuticals INDICATION Aerospan Inhalation Aerosol is indicated for the
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. [new-ka la] Mepolizumab for Injection
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr NUCALA [new-ka la] Mepolizumab for Injection Read this carefully before you start taking NUCALA and each time you
More informationQUANTITY LIMIT CRITERIA
DRUG CLASS INHALATION BRAND NAME (generic) QUANTITY LIMIT CRITERIA SHORT ACTING BETA2-ADRENERGIC AGONIST ORAL (albuterol inhalation solution) PROAIR HFA PROAIR RESPICLICK PROVENTIL HFA VENTOLIN HFA XOPENEX
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 08/19/14 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:
RITUXAN (rituximab) Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline
More informationรศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น
รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น COPD Guideline Changing concept in COPD management Evidences that we can offer COPD patients better life COPD Guidelines
More informationDipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol
Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationClinical Policy: Dupilumab (Dupixent) Reference Number: ERX.SPA.49 Effective Date:
Clinical Policy: (Dupixent) Reference Number: ERX.SPA.49 Effective Date: 06.01.17 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationDifferent kinds of asthma, different kinds of therapies
Different kinds of asthma, different kinds of therapies Friday 10 th November 2017 XXXIII Congresso Sezione SIAAIC Toscana Professor Neil Barnes Medical Head Global Respiratory Franchise, GSK Brentford,
More informationDr Rodney Itaki Lecturer Anatomical Pathology Discipline. University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology
Vasculitis Dr Rodney Itaki Lecturer Anatomical Pathology Discipline University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology Disease Spectrum Hypersensitivity vasculitis/microscopic
More informationRITUXAN (rituximab and hyaluronidase human)
Drug Prior Authorization Guideline RITUXIMAB products J9310 RITUXAN (rituximab and hyaluronidase human) PA9847 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria
More informationOral Glucocorticoid Sparing Effect of Benralizumab in Severe Asthma
Original Article Oral Glucocorticoid Sparing Effect of Benralizumab in Severe Asthma Parameswaran Nair, M.D., Ph.D., Sally Wenzel, M.D., Klaus F. Rabe, M.D., Ph.D., Arnaud Bourdin, M.D., Ph.D., Njira L.
More informationActhar Gel. H. P. Acthar Gel (corticotropin; ACTH) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.10 Subject: Acthar Gel Page: 1 of 7 Last Review Date: November 30, 2018 Acthar Gel Description H.
More information